ARDS

Aridis Pharmaceuticals, Inc. [ARDS] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

ARDS Stock Summary

Top 10 Correlated ETFs

ARDS


Top 10 Correlated Stocks

ARDS


In the News

11:51 26 Sep 2023 ARDS

Aridis (ARDS) Up on Receiving FDA's QIDP Designation for AR-301

Aridis (ARDS) achieves a milestone as the FDA granted the Qualified Infectious Disease Product designation for AR-301.

12:34 26 Sep 2023 ARDS

Aridis (ARDS) Up on Regulatory Update for Pneumonia Drug

Aridis (ARDS) announces that its AR-301 clinical program is eligible for availing the FDA's special pathway for satisfying the unmet medical need of a predefined limited population.

12:36 26 Sep 2023 ARDS

Aridis (ARDS) Up After FDA Nod for Pneumonia Drug Study Design

Aridis (ARDS) stock jumps 115% after the company reports reaching an agreement with the FDA on its proposed study on AR-301 as an adjunctive treatment for hospital-acquired pneumonia.

06:00 26 Sep 2023 ARDS

Utilizing Fundamental Analysis for Your Penny Stocks? 3 Tips

Penny stocks, often defined as shares trading for less than $5, present a unique opportunity for investors seeking high potential returns. Despite their low market price, these stocks can offer significant upside potential, particularly when approached with a well-informed strategy.

11:16 26 Sep 2023 ARDS

5 Hot Penny Stocks To Watch With Big News This Week

Whether you're trading penny stocks or higher-priced company shares, everyone wants to gain an edge. In the stock market today, there are plenty of catalysts to consider.

01:44 26 Sep 2023 ARDS

Aridis (ARDS) Stock Up as Cystic Fibrosis Study Meets Goals

Aridis Pharmaceuticals (ADRS) meets primary and secondary endpoints in a phase IIa study on AR-501 for treating cystic fibrosis.

09:04 26 Sep 2023 ARDS

Aridis Pharmaceuticals (ARDS) Reports Q3 Loss, Misses Revenue Estimates

Aridis Pharmaceuticals (ARDS) delivered earnings and revenue surprises of -4,100% and 96.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

06:48 26 Sep 2023 ARDS

Aridis Pharmaceuticals (ARDS) Reports Q2 Loss, Misses Revenue Estimates

Aridis Pharmaceuticals (ARDS) delivered earnings and revenue surprises of -650% and 97.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

11:31 26 Sep 2023 ARDS

Here's Why Aridis Pharmaceuticals (ARDS) Looks Ripe for Bottom Fishing

Aridis Pharmaceuticals (ARDS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

06:48 26 Sep 2023 ARDS

Aridis Pharmaceuticals (ARDS) Reports Q1 Loss, Lags Revenue Estimates

Aridis Pharmaceuticals (ARDS) delivered earnings and revenue surprises of 13.73% and 40.65%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

ARDS Financial details

Company Rating
Neutral
Market Cap
4.42M
Income
-9.62M
Revenue
19.65M
Book val./share
-0.41
Cash/share
0
Dividend
-
Dividend %
-
Employees
37
Optionable
No
Shortable
Yes
Earnings
20 Nov 2023
P/E
-0.41
Forward P/E
-
PEG
0.05
P/S
0.23
P/B
-0.27
P/C
-
P/FCF
-0.21
Quick Ratio
0.02
Current Ratio
0.19
Debt / Equity
-0.42
LT Debt / Equity
-0.07
-
-
EPS (TTM)
-0.65
EPS next Y
-
EPS next Q
-
EPS this Y
-52.33%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-25.23%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-241.67%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
3.97%
Inst Trans
0.34%
ROA
-148%
ROE
37%
ROC
0.53%
Gross Margin
100%
Oper. Margin
-38%
Profit Margin
-49%
Payout
-
Shs Outstand
40.21M
Shs Float
33.21M
-
-
-
-
Target Price
-
52W Range
0.051-1.7458
52W High
-
52W Low
-
RSI
48
Rel Volume
0.08
Avg Volume
1.63M
Volume
136.57K
Perf Week
20.48%
Perf Month
-37.5%
Perf Quarter
-62.28%
Perf Half Y
-75%
-
-
-
-
Beta
0.845089
-
-
Volatility
0.01%, 0.04%
Prev Close
-9.09%
Price
0.1
Change
0%

ARDS Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
Revenue per share
0.880.120.1100
Net income per share
-7.02-3.43-2.39-3.44-1.64
Operating cash flow per share
-7.71-0.96-2.23-1.87-1.55
Free cash flow per share
-7.93-0.99-2.27-1.91-1.56
Cash per share
7.72.470.91.630.26
Book value per share
8.360.43-0.95-1.15-1.29
Tangible book value per share
8.350.43-0.95-1.15-1.29
Share holders equity per share
8.360.43-0.95-1.15-1.29
Interest debt per share
0.9200.080.470.35
Market cap
34.9M37.64M55.65M28.64M22.16M
Enterprise value
10.66M16.74M48.14M14.63M23.41M
P/E ratio
-1.58-1.3-2.54-0.68-0.72
Price to sales ratio
12.6636.8355.6500
POCF ratio
-1.44-4.61-2.72-1.25-0.76
PFCF ratio
-1.4-4.52-2.67-1.22-0.76
P/B Ratio
1.3310.35-6.41-2.03-0.91
PTB ratio
1.3310.35-6.41-2.03-0.91
EV to sales
3.8716.3848.1400
Enterprise value over EBITDA
-0.41-0.58-2.15-0.33-0.79
EV to operating cash flow
-0.44-2.05-2.35-0.64-0.8
EV to free cash flow
-0.43-2.01-2.31-0.62-0.8
Earnings yield
-0.63-0.77-0.39-1.48-1.39
Free cash flow yield
-0.71-0.22-0.37-0.82-1.32
Debt to equity
0.090-0.08-0.42-0.25
Debt to assets
0.0800.050.220.42
Net debt to EBITDA
0.940.720.340.32-0.04
Current ratio
4.581.450.670.80.32
Interest coverage
-57.4200178.41-79.35
Income quality
1.10.270.920.540.96
Dividend Yield
0.04000.140
Payout ratio
-0.0600-0.10
Sales general and administrative to revenue
1.415.96.4500
Research and developement to revenue
8.3423.5616.9600
Intangibles to total assets
00000
Capex to operating cash flow
0.030.020.020.020
Capex to revenue
-0.25-0.17-0.3700
Capex to depreciation
-2.39-0.51-1.09-1.22-0.17
Stock based compensation to revenue
0.61.972.1300
Graham number
36.365.767.149.436.9
ROIC
-0.93-7.812.765.261.87
Return on tangible assets
-0.7-1.04-1.45-1.58-2.09
Graham Net
5.76-0.39-1.69-1.7-1.76
Working capital
18.94M8.64M-7.32M-6.55M-25.27M
Tangible asset value
26.28M3.6M-8.71M-14.13M-24.25M
Net current asset value
18.94M3.64M-8.68M-14.11M-27.3M
Invested capital
0.090-0.08-0.42-0.25
Average receivables
830K1.04M390.5K302.5K738.5K
Average payables
1.63M2.04M1.82M3.56M3.77M
Average inventory
-2.06M-2.26M-390.5K-302.5K-118.5K
Days sales outstanding
219.77147.5134.3200
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
1.662.472.7200
Payables turnover
00000
Inventory turnover
00000
ROE
-0.84-7.972.5231.27
Capex per share
-0.22-0.02-0.04-0.040

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q2

Metric History 2022-06-302022-09-302022-12-312023-03-31 2023-06-30
Revenue per share
0.020000.54
Net income per share
-0.46-0.51-0.24-0.240.34
Operating cash flow per share
-0.35-0.24-0.39-0.13-0.12
Free cash flow per share
-0.35-0.24-0.39-0.13-0.12
Cash per share
0.360.110.220.040
Book value per share
-1.58-2.02-1.1-0.92-0.41
Tangible book value per share
-1.58-2.02-1.1-0.92-0.41
Share holders equity per share
-1.58-2.02-1.1-0.92-0.41
Interest debt per share
0.730.790.230.130.17
Market cap
19.47M16.46M25.97M9.55M7.93M
Enterprise value
26.15M28.66M27.22M12.18M14.21M
P/E ratio
-0.59-0.45-1.21-0.330.16
Price to sales ratio
66.680000.4
POCF ratio
-3.17-3.86-3.03-2.39-1.83
PFCF ratio
-3.17-3.86-3.02-2.39-1.83
P/B Ratio
-0.7-0.46-1.07-0.34-0.53
PTB ratio
-0.7-0.46-1.07-0.34-0.53
EV to sales
89.570000.72
Enterprise value over EBITDA
-3.44-3.93-3.72-1.971.03
EV to operating cash flow
-4.26-6.72-3.18-3.04-3.27
EV to free cash flow
-4.25-6.72-3.16-3.04-3.27
Earnings yield
-0.42-0.55-0.21-0.771.53
Free cash flow yield
-0.32-0.26-0.33-0.42-0.55
Debt to equity
-0.47-0.39-0.25-0.14-0.42
Debt to assets
0.781.160.420.420.97
Net debt to EBITDA
-0.88-1.67-0.17-0.430.46
Current ratio
0.410.20.320.190.19
Interest coverage
-967.13274.527.18-231.964.56K
Income quality
0.770.521.340.59-0.36
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
5.760000.07
Research and developement to revenue
21.740000.24
Intangibles to total assets
00000
Capex to operating cash flow
000.0100
Capex to revenue
-0.040000
Capex to depreciation
-0.090-0.4900
Stock based compensation to revenue
1.180000.01
Graham number
4.064.832.462.231.77
ROIC
0.620.410.380.3-1.94
Return on tangible assets
-0.49-0.75-0.36-0.781.88
Graham Net
-2.1-2.59-1.51-1.18-0.59
Working capital
-18.42M-33.64M-25.27M-28.87M-16.51M
Tangible asset value
-27.95M-35.84M-24.25M-27.9M-14.93M
Net current asset value
-31.71M-39.31M-27.3M-30.75M-17.51M
Invested capital
-0.47-0.39-0.25-0.14-0.42
Average receivables
992K918.5K744K670K200K
Average payables
2.79M3.39M3.27M3.21M5.18M
Average inventory
00000
Days sales outstanding
489.760001.37
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
0.1800065.49
Payables turnover
00000
Inventory turnover
00000
ROE
0.290.250.220.26-0.81
Capex per share
00000

ARDS Frequently Asked Questions

What is Aridis Pharmaceuticals, Inc. stock symbol ?

Aridis Pharmaceuticals, Inc. is a US stock , located in Los gatos of Ca and trading under the symbol ARDS

What is Aridis Pharmaceuticals, Inc. stock quote today ?

Aridis Pharmaceuticals, Inc. stock price is $0.1 today.

Is Aridis Pharmaceuticals, Inc. stock public?

Yes, Aridis Pharmaceuticals, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap